Ryan E. Feaver

1.4k total citations
17 papers, 1.1k citations indexed

About

Ryan E. Feaver is a scholar working on Epidemiology, Cell Biology and Hepatology. According to data from OpenAlex, Ryan E. Feaver has authored 17 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 6 papers in Cell Biology and 6 papers in Hepatology. Recurrent topics in Ryan E. Feaver's work include Liver Disease Diagnosis and Treatment (6 papers), Endoplasmic Reticulum Stress and Disease (5 papers) and Liver physiology and pathology (3 papers). Ryan E. Feaver is often cited by papers focused on Liver Disease Diagnosis and Treatment (6 papers), Endoplasmic Reticulum Stress and Disease (5 papers) and Liver physiology and pathology (3 papers). Ryan E. Feaver collaborates with scholars based in United States, Japan and Canada. Ryan E. Feaver's co-authors include Brett R. Blackman, Brian R. Wamhoff, Bradley D. Gelfand, Banumathi K. Cole, Ajit Dash, Martin A. Schwartz, Andrew Pryor, Nicole E. Hastings, Arun J. Sanyal and Mark Lawson and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and PLoS ONE.

In The Last Decade

Ryan E. Feaver

17 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ryan E. Feaver United States 14 426 339 208 194 168 17 1.1k
Ningling Kang United States 21 675 1.6× 331 1.0× 261 1.3× 479 2.5× 198 1.2× 32 1.5k
Silvia Liu United States 21 796 1.9× 251 0.7× 85 0.4× 253 1.3× 244 1.5× 95 1.6k
Guo‐Rui Dou China 23 716 1.7× 185 0.5× 101 0.5× 143 0.7× 99 0.6× 50 1.3k
Roger van Kruchten Netherlands 14 387 0.9× 342 1.0× 78 0.4× 65 0.3× 233 1.4× 18 1.6k
Yujiro Kida Japan 19 671 1.6× 107 0.3× 106 0.5× 77 0.4× 174 1.0× 30 1.4k
Xue‐Yong Zhu China 25 710 1.7× 429 1.3× 227 1.1× 154 0.8× 166 1.0× 36 1.4k
Howard C. Masuoka United States 17 1.0k 2.4× 586 1.7× 429 2.1× 233 1.2× 342 2.0× 35 1.9k
James Surapisitchat United States 11 581 1.4× 78 0.2× 78 0.4× 101 0.5× 155 0.9× 13 946
Daniel Rodrigo‐Torres Spain 14 334 0.8× 629 1.9× 97 0.5× 565 2.9× 309 1.8× 21 1.2k
Longcheng Shang China 15 562 1.3× 172 0.5× 75 0.4× 101 0.5× 89 0.5× 21 961

Countries citing papers authored by Ryan E. Feaver

Since Specialization
Citations

This map shows the geographic impact of Ryan E. Feaver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan E. Feaver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan E. Feaver more than expected).

Fields of papers citing papers by Ryan E. Feaver

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan E. Feaver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan E. Feaver. The network helps show where Ryan E. Feaver may publish in the future.

Co-authorship network of co-authors of Ryan E. Feaver

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan E. Feaver. A scholar is included among the top collaborators of Ryan E. Feaver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan E. Feaver. Ryan E. Feaver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Feaver, Ryan E., M. Scott Bowers, Banumathi K. Cole, et al.. (2023). Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk. PLoS ONE. 18(9). e0291330–e0291330. 1 indexed citations
2.
Fanjul, Andrea, Derek M. Erion, Maria D. Paraskevopoulou, et al.. (2022). Genome-wide CRISPR Screening to Identify Drivers of TGF-β-Induced Liver Fibrosis in Human Hepatic Stellate Cells. ACS Chemical Biology. 17(4). 918–929. 13 indexed citations
3.
Shepherd, Emma L., Hiroaki Yashiro, Ryan E. Feaver, et al.. (2020). Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis. JHEP Reports. 3(2). 100217–100217. 44 indexed citations
4.
Hoang, Stephen A., Abdul M. Oseini, Ryan E. Feaver, et al.. (2019). Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease. Scientific Reports. 9(1). 12541–12541. 100 indexed citations
5.
Oseini, Abdul M., Banumathi K. Cole, Danny Issa, Ryan E. Feaver, & Arun J. Sanyal. (2018). Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis. Hepatology International. 12(1). 6–16. 21 indexed citations
6.
Cole, Banumathi K., Ryan E. Feaver, Brian R. Wamhoff, & Ajit Dash. (2017). Non-alcoholic fatty liver disease (NAFLD) models in drug discovery. Expert Opinion on Drug Discovery. 13(2). 193–205. 63 indexed citations
7.
Dash, Ajit, Robert A. Figler, Svetlana Marukian, et al.. (2016). Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicology in Vitro. 39. 93–103. 29 indexed citations
8.
Feaver, Ryan E., Banumathi K. Cole, Mark Lawson, et al.. (2016). Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis. JCI Insight. 1(20). e90954–e90954. 118 indexed citations
9.
Cole, Banumathi K., Michael B. Simmers, Ryan E. Feaver, et al.. (2015). An In Vitro Cynomolgus Vascular Surrogate System for Preclinical Drug Assessment and Human Translation. Arteriosclerosis Thrombosis and Vascular Biology. 35(10). 2185–2195. 9 indexed citations
10.
Feaver, Ryan E., Sílvia Collado, Sharon B. Hoang, et al.. (2015). FRI0069 Neutralization of IL6 by Sirukumab (SIR) Inhibits Inflammation and Cellular Stress in a Human Vascular Surrogate System of Atherosclerosis. Annals of the Rheumatic Diseases. 74. 444–445. 3 indexed citations
11.
Feaver, Ryan E., Bradley D. Gelfand, & Brett R. Blackman. (2013). Human haemodynamic frequency harmonics regulate the inflammatory phenotype of vascular endothelial cells. Nature Communications. 4(1). 1525–1525. 81 indexed citations
12.
Dash, Ajit, Michael B. Simmers, Tye Deering, et al.. (2013). Hemodynamic flow improves rat hepatocyte morphology, function, and metabolic activity in vitro. American Journal of Physiology-Cell Physiology. 304(11). C1053–C1063. 91 indexed citations
13.
Zhou, Guangjin, Anne Hamik, Lalitha Nayak, et al.. (2012). Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice. Journal of Clinical Investigation. 122(12). 4727–4731. 176 indexed citations
14.
Feaver, Ryan E., Bradley D. Gelfand, Chong Wang, Martin A. Schwartz, & Brett R. Blackman. (2010). Atheroprone Hemodynamics Regulate Fibronectin Deposition to Create Positive Feedback That Sustains Endothelial Inflammation. Circulation Research. 106(11). 1703–1711. 103 indexed citations
15.
Hastings, Nicole E., Ryan E. Feaver, Monica Y. Lee, Brian R. Wamhoff, & Brett R. Blackman. (2009). Human IL-8 Regulates Smooth Muscle Cell VCAM-1 Expression in Response to Endothelial Cells Exposed to Atheroprone Flow. Arteriosclerosis Thrombosis and Vascular Biology. 29(5). 725–731. 43 indexed citations
16.
Feaver, Ryan E., Nicole E. Hastings, Andrew Pryor, & Brett R. Blackman. (2008). GRP78 Upregulation by Atheroprone Shear Stress Via p38-, α2β1-Dependent Mechanism in Endothelial Cells. Arteriosclerosis Thrombosis and Vascular Biology. 28(8). 1534–1541. 74 indexed citations
17.
Harry, Brian L., John M. Sanders, Ryan E. Feaver, et al.. (2008). Endothelial Cell PECAM-1 Promotes Atherosclerotic Lesions in Areas of Disturbed Flow in ApoE-Deficient Mice. Arteriosclerosis Thrombosis and Vascular Biology. 28(11). 2003–2008. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ningling Kang Breakdown of academic impact, for papers by Silvia Liu Breakdown of academic impact, for papers by Guo‐Rui Dou Breakdown of academic impact, for papers by Roger van Kruchten Breakdown of academic impact, for papers by Yujiro Kida Breakdown of academic impact, for papers by Xue‐Yong Zhu Breakdown of academic impact, for papers by Howard C. Masuoka Breakdown of academic impact, for papers by James Surapisitchat Breakdown of academic impact, for papers by Daniel Rodrigo‐Torres Breakdown of academic impact, for papers by Longcheng Shang
Rankless by CCL
2026